logo
logo

Locus Biosciences Announces $23.9 Million in Funding from BARDA to Support First Phase 2 Trial of CRISPR-engineered Bacteriophage Therapy

Jan 25, 2024•over 1 year ago

Amount Raised

$23.9 Million

MorrisvilleBiotechnology

Investors

Biomedical Advanced Research And Development Authority (Barda)

Description

Locus Biosciences announced the release of $23.9 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) to support the first phase 2 trial of CRISPR-engineered bacteriophage therapy for treating urinary tract infections (UTIs) caused by drug-resistant E. coli.

Company Information

Company

Locus Biosciences

Location

Morrisville, North Carolina, United States

About

Next generation CRISPR technology for programmed cell death. Focused on developing therapies for infectious disease and the microbiome. Locus Biosciences’ novel approach to precision antimicrobials works by taking advantage of a part of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating small strands of RNA called CRISPR RNAs, which match DNA sequences specific to a given invader. When the CRISPR RNAs find a match, they activate Cas proteins that cut the DNA.

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People